AIFU Inc. - Class A Ordinary Share (AIFU)

On our desk, we are monitoring the brutal technical breakdown after AIFU collapsed more than 50% in a single trading session. Slicing through the $30 to $38 consolidation range without warning has completely destroyed the prior chart pattern. With the stock lingering just above its 52-week low, we are treating this as a binary event: either support holds for a mean-reversion bounce, or it fails and we enter unchartered territory.

Looking at the Rallies community data and recent filings, AIFU's valuation dynamics are heavily dictated by macro and regulatory cross-currents. Operating mainly through PRC subsidiaries without a VIE structure after divesting consolidated VIEs, the company faces strict regulatory commission caps and pricing interest rate controls in China. These headwinds directly pressure revenue and margin growth in its core insurance agency segment.

As a risk manager reviewing the Form F-3 shelf registration, I note that AIFU has registered up to $300,000,000 in securities alongside a massive resale offering of up to 103,747,628 Class A ordinary shares by selling shareholders. Because the company will not receive proceeds from those selling shareholder sales, the potential equity dilution and liquidity overhang represent substantial near-term risks for retail and institutional holders alike.

From a quantitative and sentiment tracking perspective, AIFU presents a fascinating divergence. While technical indicators languish at a weak 3.52/10 following the recent support failure, aggregated market sentiment and institutional fund flow metrics sit higher at 7.07/10. Meanwhile, short interest saw a notable 518% spike in late July, though absolute short interest remains minimal at roughly 0.1% of the float with a tiny 0.7 days-to-cover ratio.

Reviewing the latest 20-F annual report details, AIFU implemented a 400-for-1 share consolidation back in May 2025, leaving the capital structure with 13,435,271 Class A ordinary shares and 7,500,000 Class B ordinary shares outstanding. With consolidated net income previously reported at RMB309.5 million for 2024, the fundamental health score of 5.80/10 contrasts sharply with the frantic price action we witnessed in August 2026.